Profile: Veracyte Inc (VCYT.A)
14 Jun 2019
Veracyte, Inc., incorporated on August 15, 2006, is a genomic diagnostics company. The Company uses genomic technology to resolve diagnostic ambiguity. The Company targets diseases in which patients undergo invasive diagnostic procedures. The Company’s products combine genomic technology, clinical science and machine learning. The Company commercializes over three genomic tests, which are transforming the diagnosis of thyroid cancer, lung cancer and idiopathic pulmonary fibrosis. The Company’s commercial solution, the Afirma Thyroid fine needle aspiration (FNA) Analysis, centers on the Afirma Gene Expression Classifier (GEC). The Afirma GEC is offered directly or as part of a solution that also includes cytopathology. The Company markets and sells Afirma in the United States, in select foreign countries.
The Company operates in the pulmonology diagnostics market. The Company offers Percepta Bronchial Genomic Classifier, a genomic test to resolve ambiguity in lung cancer diagnosis. It also offers the Envisia Genomic Classifier, which is designed to help in the assessment of patients suspected to have idiopathic pulmonary fibrosis. The Company is developing and delivering genomic solutions that resolve diagnostic ambiguity and enable physicians to informed treatment decisions at an early-stage in patient care. It also offers solutions, which include Endocrinology Solution and Pulmonology Solution. The Company is also developing a molecular test to enable diagnosis of idiopathic pulmonary fibrosis (IPF) using cytology samples obtained through bronchoscopy. The Company’s operations are based in South San Francisco, California and Austin, Texas.
The Company competes with Interpace Diagnostics Group, Inc., Rosetta Genomics Ltd., Integrated Diagnostics, Inc., Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated and Sonic Healthcare USA.
6000 Shoreline Ct Ste 300
SOUTH SAN FRANCISCO CA 94080-7606